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Glucocorticoids are widely used to reduce disease activity and inflammation in patients with
a range of immune-mediated inflammatory diseases. It is uncertain whether or not low to
moderate glucocorticoid dose increases cardiovascular risk. We aimed to quantify glucocor-
ticoid dose-dependent cardiovascular risk in people with 6 immune-mediated inflammatory
diseases.
Methods and findings
We conducted a population-based cohort analysis of medical records from 389 primary care
practices contributing data to the United Kingdom Clinical Practice Research Datalink
(CPRD), linked to hospital admissions and deaths in 1998–2017. We estimated time-variant
daily and cumulative glucocorticoid prednisolone-equivalent dose-related risks and hazard
ratios (HRs) of first all-cause and type-specific cardiovascular diseases (CVDs). There were
87,794 patients with giant cell arteritis and/or polymyalgia rheumatica (n = 25,581), inflam-
matory bowel disease (n = 27,739), rheumatoid arthritis (n = 25,324), systemic lupus erythe-
matosus (n = 3,951), and/or vasculitis (n = 5,199), and no prior CVD. Mean age was 56
years and 34.1% were men. The median follow-up time was 5.0 years, and the proportions
of person–years spent at each level of glucocorticoid daily exposure were 80% for non-use,
6.0% for <5 mg, 11.2% for 5.0–14.9 mg, 1.6% for 15.0–24.9 mg, and 1.2% for�25.0 mg.
Incident CVD occurred in 13,426 (15.3%) people, including 6,013 atrial fibrillation, 7,727
heart failure, and 2,809 acute myocardial infarction events. One-year cumulative risks of all-
cause CVD increased from 1.4% in periods of non-use to 8.9% for a daily prednisolone-
equivalent dose of�25.0 mg. Five-year cumulative risks increased from 7.1% to 28.0%,
respectively. Compared to periods of non-glucocorticoid use, those with <5.0 mg daily
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prednisolone-equivalent dose had increased all-cause CVD risk (HR = 1.74; 95% confi-
dence interval [CI] 1.64–1.84; range 1.52 for polymyalgia rheumatica and/or giant cell arteri-
tis to 2.82 for systemic lupus erythematosus). Increased dose-dependent risk ratios were
found regardless of disease activity level and for all type-specific CVDs. HRs for type-spe-
cific CVDs and <5.0-mg daily dose use were: 1.69 (95% CI 1.54–1.85) for atrial fibrillation,
1.75 (95% CI 1.56–1.97) for heart failure, 1.76 (95% CI 1.51–2.05) for acute myocardial
infarction, 1.78 (95% CI 1.53–2.07) for peripheral arterial disease, 1.32 (95% CI 1.15–1.50)
for cerebrovascular disease, and 1.93 (95% CI 1.47–2.53) for abdominal aortic aneurysm.
The lack of hospital medication records and drug adherence data might have led to
underestimation of the dose prescribed when specialists provided care and overestimation
of the dose taken during periods of low disease activity. The resulting dose misclassification
in some patients is likely to have reduced the size of dose–response estimates.
Conclusions
In this study, we observed an increased risk of CVDs associated with glucocorticoid dose
intake even at lower doses (<5 mg) in 6 immune-mediated diseases. These results highlight
the importance of prompt and regular monitoring of cardiovascular risk and use of primary
prevention treatment at all glucocorticoid doses.
Author summary
Why was this study done?
• Glucocorticoids (steroids) are widely used to reduce disease activity and inflammation
in patients with a range of immune-mediated inflammatory diseases, such as rheuma-
toid arthritis, polymyalgia rheumatica, giant cell arteritis, and inflammatory bowel
disease.
• Adequate assessment of cost-effectiveness of new steroid-sparing treatments for
immune and inflammatory diseases require modelling of estimates of risk and cost of
the main treatment complications of steroids.
• It is widely recognised that high-dose steroids may increase the risk of cardiovascular
disease (CVD; heart disease, stroke, or other vascular diseases), but it is debated whether
this increase also applies to lower steroid doses.
• Earlier studies of CVD risk associated with glucocorticoid therapy failed to account for
changes in dose over time and for use of non-oral steroids and other potentially con-
founding therapies.
What did the researchers do and find?
• In 87,794 adults with immune-mediated inflammatory diseases and no prior CVD (5-
year median follow-up), we studied the risk of 6 common CVDs associated with the ste-
roid dose prescribed, quantified either as current or as cumulative dose.
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• We found strong dose-dependent risks of all CVDs, including myocardial infarction,
heart failure, atrial fibrillation, and cerebrovascular disease, in patients diagnosed with
the 6 inflammatory diseases studied.
• After 1 year, the overall absolute risk of CVD doubled for individuals using less than 5
mg prednisolone per day and was 6 times higher for users of 25 mg or greater.
• Many individuals had known modifiable cardiovascular risk factors, including current
smoking (24%), obesity (25%), or hypertension (25%).
What do these findings mean?
• We have provided evidence that individuals receiving steroids have an increased risk of
developing a broad spectrum of fatal and nonfatal CVDs and that this risk increases
with the dose of steroids and with the duration of steroid treatment.
• It was previously believed that less than 5 mg of prednisolone was safe long term, but
even at this “low dose” patients with immune-mediated inflammatory diseases have a
doubling of their underlying risk of CVD.
• New treatment approaches that avoid the need for long-term steroid treatment and
have better cardiovascular safety profile are required for immune-mediated inflamma-
tory diseases.
• All patients requiring long-term steroid treatment should be prescribed the lowest effec-
tive steroid dose and have a personalised CVD risk prevention plan that takes into
account current and prior steroid use.
Introduction
Patients with immune-mediated inflammatory diseases often receive courses of oral glucocor-
ticoids to reduce disease activity and inflammation during the initial episode and subsequent
episodic flares. Prolonged glucocorticoid treatment often causes adverse events, including car-
diovascular diseases (CVDs) [1–3]. Glucocorticoids can increase cardiovascular risk through
direct and indirect metabolic syndrome enhancement [4–6] and mineralocorticoid effects,
including cellular membrane electrolyte-mediated efflux [7–9]. However, the anti-inflamma-
tory and immune-suppressive effects of glucocorticoids can also lower or neutralise the athero-
sclerotic and vascular injury effects of chronic inflammatory diseases [10]. Demonstration of
cost-effectiveness of newly licenced glucocorticoid-sparing drugs, such as biologics, is critical
to guide their introduction for the treatment of immune-mediated inflammatory diseases in
routine healthcare. These studies require the accurate estimation of glucocorticoid dose–
response relationships to quantify cost savings associated with the toxicity profile of new
drugs.
Evidence of the relationship between glucocorticoids and CVDs comes primarily from
studies of associations with current baseline medication use or dose [2,3,7,11–16], ignoring the
doses previously administered and their changes over time, as well as the concomitant use of
other common medications that can affect the risk of CVDs (e.g., nonsteroidal anti-inflamma-
tory drugs). Many also have failed to adjust for important cardiovascular risk factors, such as
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smoking [1,2,7,13,16]. These studies have reported a dose-dependent risk of CVD with weaker
associations for daily prednisolone-equivalent doses lower than 5 to 10 mg[2,3,13,17].
Our study aimed to estimate daily and cumulative dose-dependent oral glucocorticoid car-
diovascular disease risk in people diagnosed with 6 common immune-mediated inflammatory
diseases in England, using time-dependent regression methods.
Methods
Setting and data sources
We analysed linked electronic health records from people registered at family practices in the
Clinical Practice Research Datalink (CPRD) between 1 January 1998 and 15 March 2017.
CPRD contains demographic and lifestyle data, diagnoses (e.g., stroke), prescribed medication
and results of laboratory tests and clinical examinations, prospectively recorded during pri-
mary care contacts [18]. Previous validation studies have provided evidence of the accuracy of
diagnostic and prescribing data [18]. Patients are broadly representative of the United King-
dom population with regard to age, sex, and ethnicity [18]. CPRD data were linked to hospital
records and the mortality registry (S1 Text). Hospital records from the Hospital Episode Statis-
tics (HES) (www.hscic.gov.uk/hes) contain diagnoses recorded during elective and emergency
hospital admission across all National Health Service hospitals in England. Mortality data
from the Office of National Statistics (ONS) (https://www.ons.gov.uk/atoz?query=
mortality&size=10) were used to identify dates and causes of death.
Ethical considerations
The study was approved by the Independent Scientific Advisory Committee for Medicines and
Healthcare products Regulatory Agency database research (ISAC), reference 16_146.
Study design and follow-up
This was a cohort study including all patients continuously registered in a CPRD practice for 1
year or more, aged�18 years, and free of CVD, who had been diagnosed with at least 1 of 6
immune-mediated inflammatory diseases commonly treated with oral glucocorticoids at or
before the start of follow-up (inclusion eligibility criteria). These were polymyalgia rheumatica,
giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, and inflam-
matory bowel disease (Fig A in S1 Fig). Diagnostic codes used to identify patients with each
immune-mediated inflammatory disease are shown in Table A in S1 Table. For each patient,
the follow-up started when they first became eligible (i.e., earliest date on which all the inclu-
sion criteria were met). It ended on the earliest of the following dates: occurrence of the out-
come analysed (e.g., stroke), leaving the family practice, death, or last data collection date. For
the combined analyses, patients were assigned to the immune-mediated inflammatory disease
group corresponding to the earliest condition diagnosed in the database.
Oral glucocorticoid exposure
For each prescription of oral glucocorticoids issued to the patients between 1 year before the
start and the end of the follow-up dates, recorded in CPRD, we derived the daily dose from the
recorded product name, which included information on product strength (e.g., 2 mg), direc-
tions given (e.g., 1 tablet once a day), and quantity prescribed (e.g., 28 tablets). We then esti-
mated the duration of each oral glucocorticoid prescription dividing the quantity of tablets
prescribed by the daily dose. Given the variation in relative anti-inflammatory effects of
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different types of glucocorticoids, for each prescription, we finally converted the daily dosage
into milligrams of prednisolone-equivalent dose (Table B in S1 Table).
We defined several time-variant glucocorticoid variables to quantify current and cumula-
tive drug exposure: (1) ever use from 1 year (2 or 5 years in additional sensitivity analyses)
prior to follow-up start (binary variable); (2) current daily use (i.e., whether or not the patient
was prescribed glucocorticoids at a given time point [binary variable]); (3) current daily dose
per 5 mg/day with 0 value when medication was not prescribed (continuous and categorical
variables: non-use, 1 to 4.9 mg, 5.0 to 14.9 mg, 15.0 to 24.9 mg,�25.0 mg/day); and (4) cumu-
lative dose since 1 year (2 or 5 years in additional sensitivity analyses) prior to follow-up start
per 1,000 mg (i.e., sum of the total dose prescribed up to that point divided by 1,000; consid-
ered as continuous and categorical variables: non-use, 1 to 959 mg, 960 to 3,054 mg, 3,055 to
7,299 mg, and�7,300 mg; as defined previously [19–22]).
Outcome measures
The primary outcome was the first occurrence of a composite of fatal and nonfatal CVDs (all-
cause CVD). Secondary outcomes were the first occurrence of the following common types of
CVDs: atrial fibrillation, heart failure, myocardial infarction, cerebrovascular disease, periph-
eral arterial disease, and abdominal aortic aneurysm. Diagnostic codes [23] used to define the
outcomes are listed in Table C in S1 Table and have been validated and used in multiple previ-
ous studies [24–28].
Confounding variables
We considered the following variables as a priori confounders: baseline age, sex, ethnicity,
socioeconomic status (index of multiple deprivation [26,29], area-based indicator linked
through the patient’s home postcode), smoking status, body mass index (BMI), biomarkers
(total, high- and low- density lipoprotein-cholesterol, systolic blood pressure, c-protein reac-
tive protein, and creatinine), underlying disease (e.g., rheumatoid arthritis), comorbidities
recorded in primary or hospital care (diabetes, diagnosed hypertension, cancer, asthma,
chronic obstructive pulmonary disease [COPD], and renal disease), prescribed non-oral gluco-
corticoid medication (inhaled, nasal, parenteral/intra-articular, topical, and rectal), and the
number of hospital visits 1 year before baseline. Continuous biomarker variables were
included as cubic spline in the models. We also considered time-variant prescribed medication
(disease-modifying antirheumatic drugs and nonsteroidal anti-inflammatory drugs) during
follow-up. Detailed definition of covariates is shown in S1 Text.
Statistical analysis
We replaced missing daily dose of oral glucocorticoids (i.e., during tapering periods) and con-
founders through multiple imputation with chained equations with generation of 25 datasets
(S1 Text). Models for dose imputation included patient demographics (i.e., age, sex, and index
of multiple deprivation [30]), underlying immune-mediated inflammatory disease, time
between follow-up start and prescription, type of oral glucocorticoid (e.g., prednisone), and
diagnosed comorbidities (e.g., diabetes).
We used standard descriptive statistics to describe baseline patient characteristics. We esti-
mated cumulative probabilities of CVD outcomes using cumulative incidence functions to
prevent the introduction of bias associated with the presence of competing risk of deaths [31].
We calculated incident rates with 95% confidence intervals (95% CIs) dividing the number of
patients with incident CVD by the total number of person–years of follow-up.
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We assessed the association between the outcomes and each of the oral glucocorticoid
exposures using Cox proportional hazards models adjusted for the a priori confounders, with
the practice identifier included as a random intercept to account for clustering effect. No inter-
action terms were included. The proportional hazards assumption was assessed using Schoen-
feld residuals tests. The primary analysis was based on covariate-imputed data. We generated
models for each of the 25 imputed datasets and pooled estimates and accompanying 95% CIs
following Rubin’s rules. We used 2-sided tests and considered significant at p< 0.05. We per-
formed the data management in Stata (StataCorp LP, College Station, United States of Amer-
ica; version 15) and analyses in R (http://cran.r-project.org/ The R Foundation for Statistical
Computing, Austria; version 3.3.1).
In secondary analyses, we modelled cardiovascular risk separately for men and women, for
each of the 6 immune-mediated inflammatory diseases studied, and according to duration of
these diseases at the start of follow-up (newly diagnosed/incident, within 2 years and over 2
years since diagnosis).
In sensitivity analyses, we obtained estimates from complete case models (i.e., restricted to
patients with complete covariate data), from models including covariates with a separate cate-
gory for missing data and from models unadjusted for biomarker data with a level of missing-
ness>60%. We also additionally adjusted the models for the level of disease activity. We
defined periods of active disease based on c-reactive protein and erythrocyte sedimentation
rate levels (�10 mg/mL and�30 mm/h, respectively) and the glucocorticoid daily dose
(increase in prednisolone-equivalent dose by>5 or 10 mg that was sustained for over 3 weeks)
(S1 Text).
MPR and JW had full access to all the data used in the study. All the analyses were planned
except for the sensitivity analyses additionally performed in response to peer review comments
to test the robustness of the primary analyses. These were: (1) consider longer periods of pre-
scribing prior to the index date (i.e., 2 years and 5 years) to control for protopathic bias (as
CVD is associated both with drug exposure and the indication for the exposure); and (2) pro-
pensity score adjustment of Cox proportional hazard models to balance the covariates between
exposure groups, in order to control for residual confounding by indication (details of imple-
mentation are provided in S1 Text). A summary of the generic protocol to study safety (i.e.,
risks of different types of adverse events) and associated costs of glucocorticoid therapy for the
treatment of chronic inflammatory diseases is available at https://www.cprd.com/protocol/
safety-and-associated-costs-glucocorticoid-therapy-treatment-chronic-inflammatory-diseases.
No specific protocol was written for the analyses of cardiovascular risk. This study is reported
as per the reporting of studies conducted using observational routinely collected health data
statement for pharmacoepidemiology (RECORD-PE) guideline (S1 Checklist).
Results
Patient characteristics
The study included 87,794 adults from 389 general practices with at least 1 immune-mediated
inflammatory disease diagnosed; 25,581 with polymyalgia and/or giant cell arteritis, 27,739
(31.6%) with inflammatory bowel disease, 25,324 (28.8%) with rheumatoid arthritis, 5,199
(5.9%) with vasculitis, and 3,951 (4.5%) with systemic lupus erythematosus (Table 1). A total
of 20,851 (23.7%) patients transferred out of their general practices and were lost to follow-up.
The overall mean age was 56 years (standard deviation (SD) 18.3), 29,935 (34.1%) were men,
and 21,264 (24.2%) were current smokers. At baseline, the mean duration since immune-
mediated disease diagnosis was 9.6 years (SD = 8.7; range from 6.8 years for polymyalgia and/
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N = 87,794 N = 25,581 N = 27,739 N = 25,324 N = 3,951 N = 5,199
Follow-up time (years), mean
(SD)
5.9 (4.7) 5.6 (4.3) 6.4 (5.0) 6.2 (4.8) 6.2 (4.9) 5.5 (4.4)
Total 521,161 142,216 176,547 156,846 24,567 28,343
Since first recorded disease
code
9.6 (8.7) 6.8 (5.3) 11.7 (9.9) 10.6 (9.4) 10.3 (8.4) 7.7 (6.7)
Sociodemographic
information
Males, n (%) 29,935 (34.1) 7,210 (28.2) 12,992 (46.8) 6,963 (27.5) 599 (15.2) 2,171 (41.8)
Age (years), median [IQR] 58.00 [41.00, 71.00] 72.00 [65.00, 79.00] 41.00 [31.00, 55.00] 57.00 [46.00,
68.00]
46.00 [35.00, 56.00] 50.00 [35.00,
64.00]
Ethnicity, n (%)
White 75,569 (86.1) 22,371 (87.5) 24,493 (88.3) 21,478 (84.8) 2,942 (74.5) 4,285 (82.4)
Asian 2,736 (3.1) 376 (1.5) 1,025 (3.7) 855 (3.4) 278 (7.0) 202 (3.9)
Black 1,042 (1.2) 142 (0.6) 251 (0.9) 345 (1.4) 238 (6.0) 66 (1.3)
Other 1,108 (1.3) 158 (0.6) 443 (1.6) 312 (1.2) 129 (3.3) 66 (1.3)
Index of multiple deprivation,
n (%)
First (least deprived) 15,943 (18.2) 5,080 (19.9) 5170 (18.6) 4,042 (16.0) 662 (16.8) 989 (19.0)
Fifth (most deprived) 14,356 (16.4) 3,180 (12.4) 4,583 (16.5) 4,945 (19.5) 809 (20.5) 839 (16.1)
Biomarkers, mean (SD) or
median [IQR]
BMI (kg/m2) 26.8 (5.8) 27.5 (5.6) 25.7 (5.6) 27.5 (6.1) 26.2 (5.6) 27.8 (6.6)




24.00 [10.00, 45.00] 34.00 [17.00, 58.00] 13.00 [6.00, 28.00] 21.00 [10.00,
38.00]
14.00 [7.00, 29.00] 13.00 [5.00,
27.00]
Total cholesterol (mmol/L) 5.2 (1.2) 5.2 (1.2) 5.0 (1.1) 5.2 (1.1) 5.1 (1.2) 5.1 (1.2)
HDL cholesterol (mmol/L) 1.5 (0.5) 1.5 (0.5) 1.4 (0.4) 1.4 (0.5) 1.5 (0.5) 1.4 (0.5)
LDL cholesterol (mmol/L) 3.06 (1.0) 3.07 (1.0) 3.0 (1.0) 3.10 (1.1) 3.05 (1.0) 3.06 (1.1)
Haemoglobin (mmol/L) 13.1 (1.5) 12.9 (1.4) 13.3 (1.7) 13.0 (1.5) 13.0 (1.5) 13.5 (1.5)
Creatinine (mmol/L) 78.00 [67.00, 90.00] 80.00 [69.00, 94.00] 78.00 [67.00, 90.00] 75.00 [65.00,
87.00]




134 (19.3) 141 (18.1) 126 (17.5) 134 (18.9) 127 (18.3) 132 (18.5)
Diastolic blood pressure
(mmHg)
78 (10.1) 79 (9.9) 76 (10.1) 79 (10.2) 77 (10.3) 78 (10.4)
Health behaviour
Smoking status, n (%)
Non-smoker 32,995 (37.6) 11,559 (45.2) 9,361 (33.7) 8,849 (34.9) 1,201 (30.4) 2,025 (38.9)
Ex-smoker 11,654 (13.3) 4,791 (18.7) 3,079 (11.1) 2,963 (11.7) 243 (6.2) 578 (11.1)
Current smoker 21,264 (24.2) 5,183 (20.3) 6,630 (23.9) 7,222 (28.5) 1,000 (25.3) 1,229 (23.6)
No. of hospitalisation in last
year, median [IQR]
0.00 [0.00, 1.00] 0.00 [0.00, 0.00] 0.00 [0.00, 1.00] 0.00 [0.00, 1.00] 0.00 [0.00, 1.00] 0.00 [0.00,
1.00]
Comorbidities, n (%)
Diabetes 5,602 (6.4) 2,351 (9.2) 1,107 (4.0) 1,596 (6.3) 181 (4.6) 367 (7.1)
Hypertension 22,072 (25.1) 10,810 (42.3) 3,251 (11.7) 5,960 (23.5) 736 (18.6) 1,315 (25.3)
Asthma 12,858 (14.6) 3,597 (14.1) 4,322 (15.6) 3,567 (14.1) 492 (12.5) 880 (16.9)
Chronic obstructive pulmonary
disease
2,950 (3.4) 1,280 (5.0) 498 (1.8) 999 (3.9) 59 (1.5) 114 (2.2)
(Continued)
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or giant cell arteritis and 11.7 years for inflammatory bowel disease). The most common
patient comorbidities were hypertension (25.1%), asthma (14.6%), and diabetes (6.4%).
In the year prior to follow-up start, 14,356 (16.4%) patients were prescribed oral glucocorti-
coids, 13,331 (15.2%) inhaled or nasal glucocorticoids, and 39,690 (45.2%) nonsteroidal anti-
inflammatory drugs. During follow-up, 18,877 (21.5%; range 4.2% for polymyalgia and/or
giant cell arteritis to 48.0% for rheumatoid arthritis) received disease-modifying antirheumatic
drugs.
Incidence of fatal and nonfatal cardiovascular diseases
The median time of follow-up per patient was 5.0 (interquartile range (IQR) 2.0 to 6.2) years,
and the proportions of person–years spent at each level of glucocorticoid daily exposure were
80% for non-use, 6.0% for <5 mg, 11.2% for 5.0 to 14.9 mg, 1.6% for 15.0 to 24.9 mg, and 1.2%
for�25.0 mg. A total of 13,426 incident cardiovascular events occurred (15.3% of patients)
over 541,655 person–years of follow-up (Table D in S1 Table), including 6,013 episodes of
atrial fibrillation, 4,727 of heart failure, and 2,809 of acute myocardial infarction. The inci-
dence of all-cause CVD was 24.8 per 1,000 person–years (95% CI 24.4 to 25.2). It increased













N = 87,794 N = 25,581 N = 27,739 N = 25,324 N = 3,951 N = 5,199
Cancer 5,005 (5.7) 2,259 (8.8) 998 (3.6) 1,293 (5.1) 154 (3.9) 301 (5.8)
Renal disease 1,095 (1.2) 556 (2.2) 171 (0.6) 247 (1.0) 36 (0.9) 85 (1.6)
Prescribed medication at
baseline, n (%)
Statins 8,516 (9.7) 4,437 (17.3) 1,187 (4.3) 2,198 (8.7) 235 (5.9) 459 (8.8)
Any blood pressure lowering
medication
23,755 (27.1) 11,495 (44.9) 3,645 (13.1) 6,445 (25.5) 802 (20.3) 1,368 (26.3)
Angiotensin converting enzyme
inhibitors
8,151 (9.3) 4,075 (15.9) 1,215 (4.4) 2,145 (8.5) 226 (5.7) 490 (9.4)
Angiotensin II receptor
antagonist
3,633 (4.1) 1,960 (7.7) 471 (1.7) 853 (3.4) 118 (3.0) 231 (4.4)
Prescribed medication in last
year, n (%)
Oral glucocorticoids 14,356 (16.4) 4,594 (18.0) 4,583 (16.5) 4,945 (19.5) 809 (20.5) 839 (16.1)
Inhaled or nasal glucocorticoids 13,331 (15.2) 4,523 (17.7) 3,581 (12.9) 3,895 (15.4) 474 (12.0) 858 (16.5)
Intramuscular or intra-articular
glucocorticoids
1,216 (1.4) 470 (1.8) 121 (0.4) 584 (2.3) 22 (0.6) 19 (0.4)
Rectal glucocorticoids 5,800 (6.6) 531 (2.1) 4,601 (16.6) 491 (1.9) 61 (1.5) 116 (2.2)
Topical glucocorticoids 2,094 (2.4) 647 (2.5) 615 (2.2) 525 (2.1) 139 (3.5) 168 (3.2)
Nonsteroidal anti-
inflammatory drugs
39,690 (45.2) 13,998 (54.7) 5,143 (18.5) 17,694 (69.9) 1,371 (34.7) 1,484 (28.5)
DMARDs ever during follow-
up
18,877 (21.5) 1,112 (4.3) 4,072 (14.7) 12,147 (48.0) 1,234 (31.2) 316 (6.1)
BMI, body mass index; DMARDs, disease modifying anti-rheumatic drugs; HDL-cholesterol, high-density lipoprotein-cholesterol; IQR, interquartile range; LDL-
cholesterol, low-density lipoprotein-cholesterol; SD, standard deviation.
Continuous variables were presented as mean (SD) if they were normally distributed, and median [IQR] if they were not normally distributed. Data on ethnicity, BMI,
c-reactive protein, erythrocyte sedimentation rate, total cholesterol, LDL-cholesterol, HDL-cholesterol, creatinine, systolic blood pressure, and smoking status were
missing for 8.4%, 59.1%, 68.4%, 58.2%, 74.9%, 80.4%, 84.4%, 47.7%, 36.6%, and 24.9% of patients, respectively.
https://doi.org/10.1371/journal.pmed.1003432.t001
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to 45.6 (95% CI 42.1 to 49.2) for periods of�25 mg daily dose, and from 19.9 (95% CI 19.3 to
20.5) for unexposed periods to 26.4 (95% CI 25.5 to 27.2) per 1,000 person–years for�7,300
mg cumulative those). A total of 7,940 cardiovascular events happened during periods of
nonexposure.
Cumulative probabilities of cardiovascular diseases
The cumulative incidence estimates of all-cause CVD at 1 year increased from 1.4% (95% CI
1.4% to 1.5%) for periods of non-use, through 3.8% (95% CI 3.3% to 4.2%) for <5 mg, to 8.9%
(95% CI 7.4% to 10.4%) for�25.0 mg daily dose; and were 1.6% (95% CI 1.4% to 1.7%) for
unexposed periods and 1.4% (95% CI 1.0% to 1.9%) for�7,300 mg cumulative dose (Table 2
and Table E in S1 Table). We found higher dose–response estimates in men than in women
and for atrial fibrillation and heart failure compared to other types of CVD (Table E, F, and G
in S1 Table).
Relationship between glucocorticoid dose and cardiovascular diseases
The increase in the hazard of all-cause CVD per 5 mg increase in daily dose was 1.08 (95% CI
1.07 to 1.10 per 5 mg/day), ranging from 1.07 (95% CI 1.06 to 1.09) for inflammatory bowel
disease to 1.30 (95% CI 1.22 to 1.38) for systemic lupus erythematosus (Table 3 and Table H in
S1 Table). We found strong dose–response estimates for current daily doses of<5.0 mg for all
immune-mediated diseases (hazard ratio (HR) = 1.74, 95% CI 1.64 to 1.84; range 1.52 for poly-
myalgia and/or giant cell arteritis to 2.82 for systemic lupus erythematosus), for all cardiovas-
cular outcomes, and for daily and cumulative dose (Figs 1–3, Fig B–G in S1 Fig, and Fig A–F
in S2 Fig). The highest glucocorticoid dose–response estimates were for heart failure and for
acute myocardial infarction. We found similar patterns in prespecified sensitivity analyses,
including restriction to patients with complete covariate data (Table I–M in S1 Table). Daily
and cumulative dose–response estimates were generally higher among patients with longer
underlying inflammatory disease duration and in those newly diagnosed (Table N–Q in S1
Table). Further, adjustment for the level of disease activity generally decreased the dose–
response estimates, but associations remained statistically significant (Table R and S in S1
Table). In additional sensitivity analyses performed in response to peer reviewer comments,
we found slightly higher dose–response estimates for glucocorticoid ever use when longer
lengths of glucocorticoid exposure before the start of follow-up were considered and similar
estimates for cumulative dose (Table T in S1 Table). We also found materially unchanged esti-
mates after further adjusting for propensity scores for glucocorticoid prescribing (Table U in
S1 Table).
Discussion
In this longitudinal study of 87,794 adults diagnosed with at least 1 of 6 common immune-
mediated inflammatory diseases, we quantified oral glucocorticoid dose-dependent risks of
all-cause and type-specific CVDs taking into account changes in prescribed medication over
time. At 1 year, the cumulative risk of all-cause CVD increased from 1.5% during periods with-
out medication, through 3.8% for a daily prednisolone-equivalent dose<5 mg, to 9.1% for
periods with a daily dose of�25.0 mg. We found strong dose-dependent increases in hazards
of all-cause CVD, atherosclerotic diseases, heart failure, atrial fibrillation, and abdominal aor-
tic aneurysm, regardless of the underlying immune-mediated disease, its activity, and dura-
tion. The cardiovascular risk profile of the study patients showed high prevalence of
modifiable risk factors, including current smoking (24.2% of patients), BMI�30 kg/m2
(24.5%), and hypertension (25.1%).
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Table 2. Cumulative incidence estimates of CVDs per level of current daily and cumulative oral glucocorticoid
PED.
Drug exposure variable Cumulative probability, % (95% CI)�
Incident CVD, n (%) 13,426 (15.3%)
At 1 year 2.4 (2.3–2.5)
Current daily PED, mg
non-use 1.4 (1.4–1.5)
>0.0–4.9 3.8 (3.3–4.2)
5.0–14.9 mg 4.8 (4.4–5.1)
15.0–24.9 mg 7.2 (6.1–8.3)
�25.0 mg 8.9 (7.4–10.4)






At 5 years 10.3 (10.0–10.5)












At 10 years 19.1 (18.7–19.4)












CI, confidence interval; CVDs, cardiovascular diseases; PED, prednisolone-equivalent dose.
�Unless stated otherwise. Number of patients at risk at 1, 5, and 10 years were 77,274, 44,460, and 19,562,
respectively.
https://doi.org/10.1371/journal.pmed.1003432.t002
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Previous studies have reported increased risk of composites of cardiovascular [2,3,11,12] or
coronary heart disease [1], myocardial infarction [2,3,11,14,15], heart failure [2,3,11], stroke
[2,3,16], and atrial fibrillation [7,13] in current glucocorticoid users. Some found an increased
risk of CVD only for daily doses of 5 to 10 mg or higher [13,16,17]. Estimates from previous
studies were based on current, baseline medication use [2,3,7,11–16] or dose, or average gluco-
corticoid dose in the last 6 to 12 months [1,3], without consideration of previously adminis-
tered doses and changes in dose or medication use over time. Consistent with our findings,
other studies assessing the relationship between glucocorticoid use and the risk of different
types of CVDs reported stronger associations for heart failure than for other cardiovascular
outcomes [2,3]. A summary of the methodology and major findings of previous studies is pre-
sented in our data supplement (Table V in S1 Table). This illustrates that our study is
Table 3. Associations between time-variant oral glucocorticoid PED and incident all-cause CVDs by immune-mediated inflammatory disease.












No. of events 13,426 6,267 1,937 4,236 375 611
Ever use (ref: non-use since 1
year prior to follow-up start)
1.46 (1.40–1.53) 1.25 (1.15–1.37) 1.39 (1.26–1.52) 1.63 (1.52–1.73) 1.69 (1.35–2.12) 1.52 (1.28–
1.81)
Current use (ref: non-use) 1.95 (1.87–2.02) 1.69 (1.60–1.78) 2.71 (2.43–3.02) 2.11 (1.98–2.25) 2.56 (2.02–3.25) 2.07 (1.71–
2.50)
Current daily dose per 5 mg/
day
1.09 (1.07–1.11) 1.17 (1.15–1.19) 1.08 (1.06–1.09) 1.28 (1.25–1.31) 1.28 (1.20–1.37) 1.19 (1.13–
1.25)
Current daily dose (ref: non-
use)
1.00 1.00 1.00 1.00 1.00 1.00
1–4.9 mg 1.69 (1.57–1.81) 1.50 (1.37–1.64) 2.16 (1.66–2.82) 1.84 (1.62–2.10) 2.81 (1.92–4.11) 1.92 (1.35–
2.74)
5.0–14.9 mg 1.89 (1.81–1.98) 1.70 (1.59–1.82) 2.39 (2.03–2.82) 2.00 (1.85–2.15) 2.19 (1.62–2.94) 1.92 (1.51–
2.44)
15.0–24.9 mg 2.38 (2.13–2.67) 2.07 (1.80–2.38) 3.44 (2.49–4.74) 2.79 (2.21–3.51) 2.61 (1.15–5.94) 2.46 (1.53–
3.96)
�25 mg 3.64 (3.28–4.04) 2.76 (2.30–3.32) 4.35 (3.43–5.52) 4.98 (4.11–6.03) 5.66 (3.20–10.01) 3.07 (1.92–
4.91)
Total cumulative dose per
1,000 mg
1.01 (1.01–1.01) 1.02 (1.01–1.02) 1.01 (1.01–1.01) 1.02 (1.02–1.03) 1.03 (1.01–1.04) 1.03 (1.02–
1.04)
Total cumulative dose (ref:
non-use)
1.00 1.00 1.00 1.00 1.00 1.00
1–959.9 mg 1.37 (1.29–1.45) 1.24 (1.11–1.38) 1.21 (1.06–1.38) 1.47 (1.34–1.61) 1.65 (1.20–2.26) 1.54 (1.23–
1.93)
960–3,054.9 mg 1.35 (1.28–1.43) 1.14 (1.04–1.26) 1.35 (1.18–1.54) 1.52 (1.36–1.68) 1.40 (0.95–2.06) 1.31 (0.95–
1.82)
3,055–7,299.9 mg 1.44 (1.36–1.52) 1.21 (1.10–1.33) 1.45 (1.24–1.69) 1.72 (1.55–1.90) 1.60 (1.10–2.34) 1.27 (0.94–
1.70)
�7,300 mg 1.76 (1.66–1.86) 1.50 (1.36–1.66) 1.85 (1.58–2.16) 1.80 (1.65–1.97) 2.09 (1.53–2.85) 1.91 (1.49–
2.45)
BMI, body mass index; CI, confidence interval; CVDs, cardiovascular diseases; HDL-cholesterol, high-density lipoprotein-cholesterol; HRs, hazard ratios; LDL-
cholesterol, low-density lipoprotein-cholesterol; PED, prednisolone-equivalent dose.
Hazard ratios from Cox proportional imputed models adjusted for baseline age, sex, index of multiple deprivation, smoking status, ethnicity, BMI, comorbidities
(diabetes, diagnosed hypertension, cancer, asthma, chronic obstructive pulmonary disease, and renal disease), biomarkers (total cholesterol, HDL-cholesterol, LDL-
cholesterol, c-reactive protein, and creatinine), number of hospital admissions in last year, and prescribed non-oral glucocorticoids; and time-variant use of disease-
modifying antirheumatic drugs and nonsteroidal anti-inflammatory drugs; the practice identifier was included as a random intercept to account for clustering effect.
�These estimates were additionally adjusted for the type of immune-mediated inflammatory disease diagnosed.
https://doi.org/10.1371/journal.pmed.1003432.t003
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substantially larger than most published work, offers estimates of risk for previously undefined
categories of CVD events (e.g., abdominal aortic aneurysm and peripheral arterial disease),
includes previously neglected immune-mediated inflammatory diseases (e.g., giant cell
Fig 1. Associations between time-variant oral glucocorticoid prednisolone-equivalent dose and incident atrial fibrillation and heart failure for patients with 6
immune-mediated inflammatory diseases. HRs from Cox proportional imputed models adjusted for baseline age, sex, index of multiple deprivation, smoking status,
ethnicity, BMI, type of immune-mediated inflammatory disease, comorbidities (diabetes, diagnosed hypertension, cancer, asthma, chronic obstructive pulmonary disease,
and renal disease), biomarkers (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, c-reactive protein, and creatinine), number of
hospital admissions in last year, and prescribed non-oral glucocorticoids; and time-variant use of disease-modifying antirheumatic drugs and nonsteroidal anti-
inflammatory drugs; the practice identifier was included as a random intercept to account for clustering effect. AF, atrial fibrillation; BMI, body mass index; CI, confidence
interval; HF, heart failure; HR, hazard ratio.
https://doi.org/10.1371/journal.pmed.1003432.g001
Fig 2. Associations between time-variant oral glucocorticoid prednisolone-equivalent dose and incident AMI and PAD for patients with 6 immune-mediated
inflammatory diseases. HRs from Cox proportional imputed models adjusted for baseline age, sex, index of multiple deprivation, smoking status, ethnicity, BMI, type of
immune-mediated inflammatory disease, comorbidities (diabetes, diagnosed hypertension, cancer, asthma, chronic obstructive pulmonary disease, and renal disease),
biomarkers (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, c-reactive protein, and creatinine), number of hospital admissions
in last year, and prescribed non-oral glucocorticoids; and time-variant use of disease-modifying antirheumatic drugs and nonsteroidal anti-inflammatory drugs; the
practice identifier was included as a random intercept to account for clustering effect. AMI, acute myocardial infarction; BMI, body mass index; CI, confidence interval;
HR, hazard ratio; PAD, peripheral arterial disease.
https://doi.org/10.1371/journal.pmed.1003432.g002
PLOS MEDICINE Dose-dependent oral glucocorticoid cardiovascular risks
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003432 December 3, 2020 12 / 19
arteritis), and provides more detailed quantification of glucocorticoid use. Where analysis
groups are similar, the 95% CI of our estimates overlap with those reported in previous studies
in most cases, although our intervals are smaller due to the larger size of our cohort.
The elevated absolute risk of CVD in patients receiving high doses of glucocorticoids, of
similar magnitude to that of patients with diabetes or established CVD, warrants the need to
implement and evaluate intensive lifestyle modification interventions to this high-risk group.
The dose-dependent increased risk of CVDs, including atherosclerotic diseases, heart failure,
and atrial fibrillation observed in our study, supports the need for close monitoring of cardio-
vascular risk in patients diagnosed with immune-mediated inflammatory diseases during glu-
cocorticoid treatment and in the period after therapy discontinuation. Of cardiovascular risk
scores currently used to guide decision on when to start primary cardiovascular prophylaxis,
only the QRISK3 [32] considers whether the patient is currently taking glucocorticoids (as a
binary “yes/no” predictor that ignores dose and recent exposure) and whether he/she is diag-
nosed with rheumatoid arthritis or systemic lupus erythematosus. Further refinements of this
risk prediction tool, taking into account cumulative and/or current dose, might therefore
improve its performance to identify patients in need for primary cardiovascular prevention.
Our findings also emphasise the importance of rapid glucocorticoid dose tapering and discon-
tinuation as soon as disease control is achieved, as well as the importance of evaluating the
safety profile of alternative therapeutic options for patients with autoimmune-mediated
inflammatory diseases.
This study has some key strengths. The estimation of drug dose–response risks in this pop-
ulation-based cohort of all people with immune-mediated inflammatory diseases with differ-
ent levels of activity and duration minimised the introduction of selection bias and increased
the generalisability of the results. The use of linked health data from primary care and hospital
facilities and the mortality registry, and diagnostic codes extensively used and validated for
Fig 3. Associations between time-variant oral glucocorticoid prednisolone-equivalent dose and incident cerebrovascular disease and AAA for patients with 6
immune-mediated inflammatory diseases. HRs from Cox proportional imputed models adjusted for baseline age, sex, index of multiple deprivation, smoking status,
ethnicity, BMI, type of immune-mediated inflammatory disease, comorbidities (diabetes, diagnosed hypertension, cancer, asthma, chronic obstructive pulmonary disease,
and renal disease), biomarkers (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, c-reactive protein, and creatinine), number of
hospital admissions in last year, and prescribed non-oral glucocorticoids; and time-variant use of disease-modifying antirheumatic drugs and nonsteroidal anti-
inflammatory drugs; the practice identifier was included as a random intercept to account for clustering effect. AAA, abdominal aortic aneurysm; BMI, body mass index;
CI, confidence interval; CVA, cerebrovascular disease; HR, hazard ratio.
https://doi.org/10.1371/journal.pmed.1003432.g003
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cardiovascular research [25–28,33,34], increased ascertainment of the study population and all
the outcomes assessed. Estimates of positive predictive values reported in validation studies for
the diseases of interest are�75%. Information on prescribed medication is prospectively col-
lected and includes all prescriptions issued in primary care, where patients with immune-
mediated diseases are primarily treated. We derived the dose of oral glucocorticoids and the
duration of prescribed medication from the directions given to patients on how to take their
treatment. During periods of dose tapering, when these directions were unspecific (e.g., writ-
ten “as directed”), we used the longitudinal doses prescribed to the patients to impute the dose
taken. We minimised time-related bias through use of time-variant medication variables (both
exposure and confounders) and a start of patient follow-up that was unrelated to the start or
use of glucocorticoid therapy. We adjusted HRs for established cardiovascular risk factors
(e.g., smoking, hypertension, and diabetes), concomitant use of medications (e.g., time-variant
disease-modifying antirheumatic drugs, nonsteroidal anti-inflammatory drugs, and non-oral
glucocorticoid use). In the primary analysis, we used multiple imputation to handle missing
baseline biomarkers and smoking data. We found similar patterns of dose–response in sensi-
tivity analyses, including analyses in which we used a separate category for missing covariate
data, in those restricted to individuals with complete covariate data, and in those unadjusted
for baseline biomarker information with high level of missingness (>60% of patients).
However, this study also has limitations. The lack of data on hospital prescribed medication
and on drug adherence is likely to have resulted in underestimation of the dose taken when
specialists treated the patients and might have overestimated the dose taken in periods of low
disease activity for some patients. The resulting misclassification is likely to have reduced the
size of dose–response estimates. Furthermore, although the main purpose of the study was to
provide estimates of oral glucocorticoid dose–response for patients with the inflammatory dis-
eases studied without making aetiological inferences, associations might be confounded by
indication of glucocorticoid therapy and affected by unmeasured confounding. We therefore
examined the effect of confounding by indication and ascertainment bias through adjustment
by periods of disease activity and disease-modifying antirheumatic drugs use and performing
analyses according to duration of the underlying disease. The resulting dose–response associa-
tions remained strong and statistically significant, and estimates obtained when propensity
score model adjustment was used to balance drug exposure groups did not change.
In conclusion, we reported improved estimates of dose-dependent risks of CVDs. Our find-
ings highlight the importance of implementing and evaluating targeted intensive cardiovascu-
lar risk factor modification interventions; promptly and regularly monitor patient
cardiovascular risk, beyond diagnosis of inflammatory arthropathies and systemic lupus ery-
thematosus, even when prescribing low prednisolone-equivalent doses; and the need for refin-
ing existing risk prediction tools for primary prevention of CVDs. Furthermore, the estimates
of risk can be used to conduct cost-effectiveness and benefit–harm evaluations that guide the
introduction of newly licenced glucocorticoid-sparing drugs for the treatment of immune-
mediated inflammatory diseases. These estimates are to be complemented by future work on
the estimation of risk of cardiovascular events beyond the first occurrence of CVD that are
considered in calculations of glucocorticoid-associated costs.
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